Osterweis Capital Management Inc Ligand Pharmaceuticals Inc Transaction History

Osterweis Capital Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$105.93 - $142.47 $5.93 Million - $7.97 Million	-55,974 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $3.39 Million - $7.2 Million	26,440 Added 89.52%	55,974 $7.6 Million
Q3 2018 Nov 13, 2018	BUY	$211.18 - $274.49 $25,341 - $32,938	120 Added 0.41%	29,534 $8.11 Million
Q2 2018 Aug 13, 2018	SELL	$150.77 - $207.98 $1.84 Million - $2.53 Million	-12,180 Reduced 29.28%	29,414 $6.09 Million
Q1 2018 May 14, 2018	BUY	$138.63 - $182.62 $966,251 - $1.27 Million	6,970 Added 20.13%	41,594 $6.87 Million
Q4 2017 Feb 14, 2018	SELL	$128.36 - $147.04 $657,845 - $753,580	-5,125 Reduced 12.89%	34,624 $4.74 Million
Q3 2017 Nov 13, 2017	BUY	$120.91 - $137.94 $4.81 Million - $5.48 Million	39,749	39,749 $5.41 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.01B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Osterweis Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Osterweis Capital Management Inc with notifications on news.